Abbott Laboratories (ABT) : Trust Co Of Vermont scooped up 11,813 additional shares in Abbott Laboratories during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 18, 2016. The investment management firm now holds a total of 179,753 shares of Abbott Laboratories which is valued at $7,666,465.Abbott Laboratories makes up approximately 0.99% of Trust Co Of Vermont’s portfolio.
Other Hedge Funds, Including , Leavell Investment Management reduced its stake in ABT by selling 305 shares or 0.7% in the most recent quarter. The Hedge Fund company now holds 43,040 shares of ABT which is valued at $1,835,656. Abbott Laboratories makes up approx 0.26% of Leavell Investment Management’s portfolio.Mitchell Mcleod Pugh Williams Inc boosted its stake in ABT in the latest quarter, The investment management firm added 101 additional shares and now holds a total of 7,182 shares of Abbott Laboratories which is valued at $302,290. Abbott Laboratories makes up approx 0.22% of Mitchell Mcleod Pugh Williams Inc’s portfolio.Newman Dignan Sheerar reduced its stake in ABT by selling 50 shares or 0.67% in the most recent quarter. The Hedge Fund company now holds 7,420 shares of ABT which is valued at $310,824. Abbott Laboratories makes up approx 0.20% of Newman Dignan Sheerar’s portfolio.Nadler Financial Group reduced its stake in ABT by selling 1,508 shares or 12.17% in the most recent quarter. The Hedge Fund company now holds 10,880 shares of ABT which is valued at $455,763. Abbott Laboratories makes up approx 0.19% of Nadler Financial Group’s portfolio.Moreno Evelyn V boosted its stake in ABT in the latest quarter, The investment management firm added 500 additional shares and now holds a total of 80,280 shares of Abbott Laboratories which is valued at $3,362,929. Abbott Laboratories makes up approx 1.26% of Moreno Evelyn V’s portfolio.
Abbott Laboratories opened for trading at $42.8 and hit $42.92 on the upside on Wednesday, eventually ending the session at $42.65, with a gain of 2.03% or 0.85 points. The heightened volatility saw the trading volume jump to 1,36,86,493 shares. Company has a market cap of $62,659 M.
On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.
Many Wall Street Analysts have commented on Abbott Laboratories. Abbott Laboratories was Upgraded by Edward Jones to ” Buy” on Jun 21, 2016.
Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.